Patents by Inventor Athena Spanoyannis

Athena Spanoyannis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Post-translational modifications and clostridial neurotoxins
    Patent number: 8119767
    Abstract: The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.
    Type: Grant
    Filed: January 17, 2007
    Date of Patent: February 21, 2012
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Athena Spanoyannis, K. Roger Aoki, Wei-Jen Lin
  • POST-TRANSLATIONAL MODIFICATIONS AND CLOSTRIDIAL NEUROTOXINS
    Publication number: 20110046356
    Abstract: The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.
    Type: Application
    Filed: January 17, 2007
    Publication date: February 24, 2011
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Athena Spanoyannis, K. Roger Aoki, Wei-Jen Lin
  • Post-translational modifications and Clostridial neurotoxins
    Patent number: 7893202
    Abstract: The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.
    Type: Grant
    Filed: January 17, 2007
    Date of Patent: February 22, 2011
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Athena Spanoyannis, K. Roger Aoki, Wei-Jen Lin
  • Post-translation modification and clostridial neurotoxins
    Patent number: 7888469
    Abstract: The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.
    Type: Grant
    Filed: January 17, 2007
    Date of Patent: February 15, 2011
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Athena Spanoyannis, K. Roger Aoki, Wei-Jen Lin
  • POST-TRANSLATIONAL MODIFICATIONS AND CLOSTRIDIAL NEUROTOXINS
    Publication number: 20100273985
    Abstract: The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.
    Type: Application
    Filed: January 17, 2007
    Publication date: October 28, 2010
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Athena Spanoyannis, K. Roger Aoki, Wei-Jen Lin
  • POST-TRANSLATIONAL MODIFICATION AND CLOSTRIDIAL NEUROTOXINS
    Publication number: 20100273986
    Abstract: The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.
    Type: Application
    Filed: January 17, 2007
    Publication date: October 28, 2010
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Athena Spanoyannis, K. Roger Aoki, Wei-Jen Lin
  • Post-translational modifications and Clostridial neurotoxins
    Patent number: 7223577
    Abstract: The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.
    Type: Grant
    Filed: May 31, 2005
    Date of Patent: May 29, 2007
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Athena Spanoyannis, K. Roger Aoki, Wei-Jen Lin
  • Post-translational modifications and Clostridial neurotoxins
    Publication number: 20060258843
    Abstract: The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.
    Type: Application
    Filed: May 31, 2005
    Publication date: November 16, 2006
    Inventors: Lance Steward, Ester Fernandez-Salas, Athena Spanoyannis, K. Aoki, Wei-Jen Lin
  • Modified clostridial neurotoxins with altered biological persistence
    Publication number: 20020127247
    Abstract: The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.
    Type: Application
    Filed: October 31, 2001
    Publication date: September 12, 2002
    Applicant: Allergen Sales, Inc.
    Inventors: Lance E. Steward, Athena Spanoyannis, Kei Roger Aoki, Wei-Jen Lin